MYOMO INC (NYSEARCA:MYO) delivered second-quarter revenue and adjusted earnings that came in above analyst expectations, along with a raised full-year outlook. The wearable medical robotics company generated $11.7 million in revenue, topping the roughly $10.5 million consensus, and reported a non-GAAP loss per share of $0.07, better than the $0.10 loss analysts had expected. Shares rose about 8.5% in after-hours trading, suggesting investors were encouraged by the earnings surprise and the stronger guidance.
Quarterly results vs. estimates
Revenue of $11.7 million exceeded the consensus estimate by roughly 12%, while the adjusted loss per share came in narrower than the $0.10 loss forecast. The top-line result also reflected a 21% gain from the prior-year period, with revenue recognized on 211 MyoPro units, up 19% year over year.
Key second-quarter metrics
- Revenue: $11.7 million actual vs. $10.5 million consensus
- Non-GAAP EPS: -$0.07 actual vs. -$0.10 consensus
- Gross margin: 72.1%, up from 62.7% a year ago
- Operating expenses: $10.7 million, up less than 1% year over year
- Adjusted EBITDA loss: $0.8 million, versus a $4.0 million loss in Q2 2025
- Orders: 255, a record and up 23% year over year
The company also highlighted a shift in revenue mix. Referral-based revenue, including provider referrals, orthotic and prosthetic partners and the Department of Veterans Affairs, accounted for 53% of second-quarter revenue, up from 26% in the year-ago quarter. MyoConnect pipeline additions rose 40% sequentially, and payer expansion continued with in-network access to more than 100 million covered lives.
Guidance comes in ahead of forecasts
Management raised its full-year revenue guidance to $45 million to $47 million. The midpoint of that range, $46 million, is above the full-year consensus of approximately $44.9 million. For the third quarter, the company expects revenue of $11.5 million to $12.0 million, which is above the $11.3 million analyst estimate for the period. The company also reiterated its full-year operating leverage expectation and said cash burn in the second half should be less than $2 million.
Market reaction and what it means
The after-hours move of roughly 8.5% points to a positive reception from investors, with attention focused on the revenue beat, the narrower adjusted loss and guidance above consensus. The stock had already shown strength over the previous week, so the earnings report appears to be adding momentum rather than reversing a trend.
Even so, Myomo remains unprofitable at the operating and net income levels. The company posted a $2.3 million operating loss and a $4.0 million net loss in the quarter, including a $1.2 million non-cash derivative charge. Cash, cash equivalents and short-term investments totaled $13.5 million at June 30, leaving financing and scaling risks as factors to monitor.
More data to follow
Investors who want to review more historical earnings information can visit the earnings page. For updated analyst estimates and projections, see the latest forecast data.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Myomo (NYSEARCA:MYO) Beats Q2 Estimates and Raises Full-Year Revenue Guidance
MYOMO INC (NYSEARCA:MYO) delivered second-quarter revenue and adjusted earnings that came in above analyst expectations, along with a raised full-year outlook. The wearable medical robotics company generated $11.7 million in revenue, topping the roughly $10.5 million consensus, and reported a non-GAAP loss per share of $0.07, better than the $0.10 loss analysts had expected. Shares rose about 8.5% in after-hours trading, suggesting investors were encouraged by the earnings surprise and the stronger guidance.
Quarterly results vs. estimates
Revenue of $11.7 million exceeded the consensus estimate by roughly 12%, while the adjusted loss per share came in narrower than the $0.10 loss forecast. The top-line result also reflected a 21% gain from the prior-year period, with revenue recognized on 211 MyoPro units, up 19% year over year.
Key second-quarter metrics
The company also highlighted a shift in revenue mix. Referral-based revenue, including provider referrals, orthotic and prosthetic partners and the Department of Veterans Affairs, accounted for 53% of second-quarter revenue, up from 26% in the year-ago quarter. MyoConnect pipeline additions rose 40% sequentially, and payer expansion continued with in-network access to more than 100 million covered lives.
Guidance comes in ahead of forecasts
Management raised its full-year revenue guidance to $45 million to $47 million. The midpoint of that range, $46 million, is above the full-year consensus of approximately $44.9 million. For the third quarter, the company expects revenue of $11.5 million to $12.0 million, which is above the $11.3 million analyst estimate for the period. The company also reiterated its full-year operating leverage expectation and said cash burn in the second half should be less than $2 million.
Market reaction and what it means
The after-hours move of roughly 8.5% points to a positive reception from investors, with attention focused on the revenue beat, the narrower adjusted loss and guidance above consensus. The stock had already shown strength over the previous week, so the earnings report appears to be adding momentum rather than reversing a trend.
Even so, Myomo remains unprofitable at the operating and net income levels. The company posted a $2.3 million operating loss and a $4.0 million net loss in the quarter, including a $1.2 million non-cash derivative charge. Cash, cash equivalents and short-term investments totaled $13.5 million at June 30, leaving financing and scaling risks as factors to monitor.
More data to follow
Investors who want to review more historical earnings information can visit the earnings page. For updated analyst estimates and projections, see the latest forecast data.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »